When you stop tirzepatide, the drug clears over a few weeks, appetite returns, and most people regain a large share of the weight within a year. In SURMOUNT-4, adults switched to placebo after 36 weeks regained 14.0% of body weight over the next 52 weeks, while those who continued lost a further 5.5%. The label lists no withdrawal syndrome. Stopping is safe to do without a taper, but talk to your prescriber first. If you are new to the drug, start with our tirzepatide guide.
Key takeaways
- Tirzepatide's elimination half-life is about 5 days. After five half-lives, about 25 days, only about 3% of the last dose remains.
- SURMOUNT-4: +14.0% regain over 52 weeks after switching to placebo, versus a further -5.5% on continued tirzepatide.
- The label does not describe a withdrawal syndrome or a taper. What comes back is appetite, and with it, weight.
- The label does tell you to stop in specific situations: suspected pancreatitis, a serious allergic reaction, and pregnancy.
- Compounded tirzepatide is not FDA approved; the same clearance and regain logic applies because the molecule is the same.
The first month after your last dose: clearance timeline
Tirzepatide leaves the body slowly, which is why one missed dose barely matters and why stopping is gradual rather than sudden. The label gives a half-life of about 5 days. The table is arithmetic on that figure.
| Days since last dose | Half-lives | Approximate share of last dose remaining |
|---|---|---|
| 5 | 1 | 50% |
| 10 | 2 | 25% |
| 15 | 3 | 12.5% |
| 20 | 4 | About 6% |
| 25 | 5 | About 3% |
Source: elimination half-life of about 5 days from the Zepbound and Mounjaro prescribing information; the percentages are arithmetic, not measured values.
In practice, the appetite effect fades over those weeks rather than switching off on a single day. Side effects that track drug level, such as nausea and constipation, would be expected to ease over the same period, although the trials did not measure recovery after stopping. More on clearance is at how long tirzepatide stays in your system.
Tirzepatide weight regain after stopping: the SURMOUNT-4 numbers
SURMOUNT-4 was designed to answer this question. After 36 weeks of tirzepatide, with a mean loss of 20.9%, participants were randomized to continue or to switch to placebo for 52 more weeks. Everyone kept receiving lifestyle counseling.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →| Measure | Continued tirzepatide | Switched to placebo |
|---|---|---|
| Loss during the 36-week lead-in | -20.9% (mean, all participants) | -20.9% (mean, all participants) |
| Change over the next 52 weeks | Further -5.5% | +14.0% |
| Share of the lead-in loss returned (arithmetic) | None | About two thirds |
Source: SURMOUNT-4, Aronne et al., JAMA 2024. The last row is arithmetic (14.0 divided by 20.9).
The regain was not instant, and it was not total in the trial's 52-week window, but it was large despite counseling. That is the honest expectation. Weight gain after stopping Zepbound is the norm in the data, not a personal failure.
Is there tirzepatide withdrawal?
Not in the sense of a withdrawal syndrome. The label does not list one, and there is no physical dependence described. What people call "withdrawal" is usually three things happening at once: hunger returning as the drug clears, food staying in the stomach for less time so you feel empty sooner, and the loss of the routine. None of those require medical treatment, but all of them make regain likely without a plan. If you stopped because of side effects, tell your prescriber which ones; if you stopped for cost, see the pricing note below.
Side effects of stopping Zepbound
The label lists no adverse reactions from discontinuation itself. Two label points do matter after stopping. First, if you switched to a non-oral contraceptive or added a barrier method because of the interaction, the label's 4-week rule was about starting and dose increases; ask your prescriber before changing back. Second, if you were taking insulin or a sulfonylurea at a reduced dose because of hypoglycemia risk, blood sugar control changes when tirzepatide clears, so those doses need review. For people with type 2 diabetes on Mounjaro, A1c would be expected to drift back up; SURPASS-1 showed A1c reductions of 1.87 to 2.07 points on treatment, and that benefit depends on continuing.
When the label says to stop
| Situation | Label instruction |
|---|---|
| Suspected acute pancreatitis (severe, persistent abdominal pain) | Discontinue; do not restart if confirmed |
| Serious hypersensitivity reaction | Discontinue and seek care |
| Pregnancy recognized | Zepbound: discontinue, because weight loss offers no benefit in pregnancy and tirzepatide may cause fetal harm |
| Planned general anesthesia or deep sedation | Tell the anesthesia team; the label warns of pulmonary aspiration risk |
Source: Zepbound and Mounjaro prescribing information, Warnings and Precautions; Use in Specific Populations.
How to keep weight off after tirzepatide
The only strategy tested head to head is staying on the drug, and the label sets no maximum duration. If you are stopping anyway, the tools are the ones the label names as part of the indication, a reduced-calorie diet and increased physical activity, plus follow-up. No trial in our sources tested a specific off-drug maintenance protocol, so be wary of pages that promise a percentage. A restart, if you and your prescriber choose one, follows the label's escalation from 2.5 mg. See how to keep weight off after Zepbound and tirzepatide maintenance dose after goal weight.
What this means for compounded tirzepatide
Compounded tirzepatide is not FDA approved and is not interchangeable with Zepbound or Mounjaro; a licensed provider decides whether it is appropriate. Cost is the most common reason people stop. Brand vials run $299 to $699 a month through LillyDirect depending on dose. At FormBlends, compounded tirzepatide is $149 for the first month, then $239 a month, or $214 a month with Subscribe & Save, at any dose. If cost is the reason you are considering stopping, compare pricing before you decide, and talk to your prescriber about the SURMOUNT-4 regain data.
Frequently Asked Questions
What happens when you stop taking tirzepatide?
The drug clears over about 25 days, appetite returns, and weight tends to come back. In SURMOUNT-4, adults who switched to placebo regained 14.0% of body weight over 52 weeks while those who continued lost 5.5% more.
Is there tirzepatide withdrawal?
The label lists no withdrawal syndrome and no taper. Returning hunger and the loss of routine are what people notice. Side effects tied to drug level would be expected to fade as the drug clears.
How much weight do you gain after stopping Zepbound?
The only trial figure is SURMOUNT-4: a mean regain of 14.0% of body weight over 52 weeks after stopping, about two thirds of the 20.9% lost. Individual results vary.
Can you just stop taking tirzepatide?
The label does not require a taper. But talk to your prescriber first, especially if you take insulin or a sulfonylurea, changed contraception, or stopped because of a side effect that needs follow-up.
How do I keep the weight off after tirzepatide?
Staying on a maintenance dose is the only tested method. If you stop, the label's diet and activity foundation plus regular weigh-ins and a restart threshold agreed with your prescriber is the practical plan.
Sources
- Zepbound (tirzepatide) prescribing information, Eli Lilly via DailyMed, revised 08/2026.
- Mounjaro (tirzepatide) prescribing information, Eli Lilly via DailyMed, revised 08/2026.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4), Aronne et al., JAMA, 2024.
- Efficacy and safety of once-weekly tirzepatide monotherapy in type 2 diabetes (SURPASS-1), Rosenstock et al., The Lancet, 2021.
- FormBlends pricing, Form Blends LLC, verified September 5, 2026.
Next steps
Read how to keep weight off after Zepbound and tirzepatide average weight loss per week for the other side of the curve. Browse the tirzepatide hub for every other tirzepatide question. Talk to a clinician before you stop. Compounded tirzepatide is not FDA approved and is not interchangeable with Zepbound or Mounjaro; a licensed provider decides whether it is appropriate for you.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →